Roy Exum: My Pimples And Andrea Sloan

Monday, September 30, 2013 - by Roy Exum
Roy Exum
Roy Exum

A real long time ago I was having a fit with acne. I was a lovelorn teenager, infatuated with pretty girls in a dizzy game where pimples can really become cumbersome. It seemed like nothing was working and, after I grew a pimple large enough for its own zip code, I finally found a genius doctor who quickly became my lifelong hero when he came up with a marvelous idea.

At the time there was a new “super drug”  that was languishing through years of “clinical trials” in the United States and nobody could get any, despite the fact the revolutionary medicine was already available in Germany. My hero called up a close friend who was a German doctor and – presto! – the first 250 pills came flying across the ocean.

I had to promise that I would not sue anybody if I grew an extra set of ears, developed female breasts, or my eyes turned yellow, but, honestly, I would have dyed my hair green to get the American-made medicine. After I took a course of what was then identified by only a strange laboratory number, my pimples and my acne were gone forever. I had Clark Gable looks and never looked back. That’s a true story (except the Gable part.)

Other fellow Americans had to wait for many months. I don’t believe that's right. Since this occurred in my formative years, I have cursed the federal Food and Drug Administration for much of my adult life because the “clinical trials” process we use is horribly dysfunctional and in critical need of an overhaul.

To illustrate my point, allow me to introduce a beautiful Texas lawyer, Andrea Sloan. Yes, she is quite pretty but “beautiful” because her career has been as the executive director of a Texas advocacy project that provides free legal services to low-income victims of domestic or sexual abuse.

Andrea is a victim herself, not just of stage 3c ovarian cancer but a horribly-tangled FDA system. Her doctors have exhausted every known method to save her life. Six years of surgery, radiation, and chemotherapy haven’t worked. She’s still very much a patient at the world-famous M.D. Anderson Medical Center and her oncologist believes an experimental drug called “BMN 673” might well save Andrea’s life.

M.D. Anderson has a good supply of BMN 673 on hand but with millions of dollars at stake, the manufacturer, BioMarin in California, has said no. “It would be unethical and reckless to provide end-stage refractory ovarian cancer patients outside clinical trial with BMN 673 at this early stage of development,” said spokesperson Debra Charlesworth.

“If we did,” Charlesworth explained to CNN, “we would be exposing the experimental drug to a large group without adequate testing. There have been previous circumstances where early access to large groups has resulted in adverse consequences that were worse than the course of the disease.”

I am certain no scientist can hardly wait for somebody to try to explain to me what “adverse consequences” could possibly be worse than what Andrea Sloan is facing without BMN 673. Andrea is pleading for the drug – let the petals of the flower fall where they may – and probably understands the risks as much as anyone involved. She knows what will happen if she fails to get BMN 673 better than anyone else, too.

Here is what she wrote in a statement to the drug company: “I recognize the importance of weighing the risk and the myriad of considerations they face as a company. However, this is a risk worth taking. I will thank them. My family will thank them. An amazing army of loyal supporters, to whom I owe a debt of gratitude, will thank them. In America we do not leave our wounded warriors on the battleground. BioMarin, please be the Calvary that saves me.”

Her M.D. Anderson doctors believe Andrea is a great candidate. Further, the FDA itself has just announced Ms. Sloan qualifies for a “compassionate care” waiver in the rules but the manufacturer, BioMarin, still says no. The word is BioMarin stands to make about $500 million on the drug and, even though they say they plan to give away 10 percent of the medicine to charity, they refuse to face the ethical dilemma.

As of Sunday afternoon Andrea had almost 170,000 supporters on her Change.org webpage and politician Newt Gingrich, co-host of CNN’s “Crossfire” program, is irate at “a corporation protecting its wallet at the expense on Andrea’s possibly dying. If you want to know why big companies often get bad names, it’s explaining that clerical support to fill out FDA paperwork is too difficult when you can save a life.”

Dr. Charles Levenback, Andrea’s doctor, is disappointed at BioMarin’s stance but, as a man who sees the fight against cancer every day, he told CNN reporters, “My own belief is that the drug companies, the manufacturers, the insurance companies, the providers like my hospital M.D. Anderson, the individual medical professionals, the investigators, the patients -- everybody wants the same things. Safe, effect, novel therapies for as many people as it's appropriate for. Even BioMarin, I believe. I don't think this is like 'Let the masses eat cake.' I think they're on the same mission. But the whole system is giving this dysfunctional result."

On Andrea Sloan’s Facebook page there is a picture that tells of “Three Simple Rules.” The text reads, “If you don’t go after what you want in life, you will never have it. If you don’t ask, the answer will always be No. If you don’t step forward, you’ll always be in the same place.”

Those three rules got rid of my pimples but all we can do is pray for Andrea Sloan. She needs it right now.

royexum@aol.com


Send Your Opinions To Chattanoogan.com; Include Your Full Name, Address, Phone Number For Verification

We welcome your opinions at Chattanoogan.com. Email to  news@chattanoogan.com . We require your real first and last name and contact information. This includes your home address and phone number. We do not post the contact information, but need it for verification. There is no word limit, but if your article is too long you may lose your reader. Please focus more ... (click for more)

Lawsuit May Bring More Security To Hamilton Place Mall

Good for the military veteran that is suing for getting shot on CBL's and ERMC's watch. With this past holiday season's traumatic events unfolding at the mall and clear evidence that ERMC security does not have the ability to insure the safety of the patrons, it is time for a lawsuit to get someone's attention.  This military veteran, who clearly saw combat due to the mentioned ... (click for more)

Witness Says Morse Told Him "His Emotions Got The Best Of Him" At Triple Killing In Lookout Valley

A witness told a Criminal Court jury on Friday that Derek Morse told him "his emotions got the best of him" at a triple killing in Lookout Valley. Michael Shavers also said Morse told him in detail about the slayings of John "Jake" Lang, Jon Morris and Caleb Boozer and the shooting of Matthew Callan at the Rolling Hills Trailer Park on April 9, 2014. Morse is standing trial ... (click for more)

Demetrius Buchanan Taken Into Custody For Murder Of Langdon Strickland, Who Was Shot On South Kelly Street

Demetrius Buchanan has been taken into custody for the murder of 33-year-old Langdon Strickland, who was shot on South Kelly Street on Aug. 14. He died three days later from a single gunshot to the head.   Buchanan is charged with f irst-degree murder, possession of a firearm during the commission of a dangerous felony and reckless endangerment.   Chattanooga ... (click for more)

Unbeaten Baylor Rolls Past Cleveland For 30th win

The Baylor Lady Red Raiders have produced more than their share of outstanding volleyball teams in head coach Sarah Lail’s tenure, but this year’s team may be the best ever. There are no real superstars like in years past, but they have a talented group of young ladies who can beat you from any number of spots on the court. Facing one of its biggest tests of the season on ... (click for more)

Vols, UMass Matchup Pits 1998 National Champions

Tennessee takes on UMass on Saturday at Neyland Stadium. The game will feature a noon ET kickoff on SEC Network.     Tennessee (2-1) is coming off a 26-20 road loss to Florida on Sept. 16. Junior running back John Kelly set career highs with 141 rushing yards and 96 receiving yards and played a major role in the Vols' second half rally before the Gators ... (click for more)